Cure51

Cure51: Decodes exceptional cancer survivors’ biology to identify targets for new cancer therapies. BioTech · Series A · Paris, France. Rated 64/100 on…

Decodes exceptional cancer survivors’ biology to identify targets for new cancer therapies.

Preliminary profile · public data only

Startup24 listed Cure51 from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

• Category: BioTech (Oncology target discovery and precision medicine)
• Stage: Series A
• Location: Paris, France

Startup24 rating: 64/100

Cure51 addresses a substantial oncology discovery opportunity with a differentiated exceptional-survivor approach and a potentially defensible international clinical-data network.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

• How the score is calculated
• Browse the catalogue

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.